Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

WOODEN MAN PUSHING SLEEP APNEA ROCK UPHILL.
Apnimed hopes its combo drug can provide a drug therapy to a wide range of OAS patients • Source: Alamy

Obstructive sleep apnea (OSA) is a therapeutic area with an entrenched therapy – continuous positive air pressure (CPAP) devices – but with the first Phase III data in hand for its combination pill AD109, Apnimed thinks it can enter the market as a monotherapy in OSA or be used in tandem with CPAP or Eli Lilly’s Zepbound (tirzepatide).

Key Takeaways
  • Apnimed reported Phase III success for its sleep apnea combination pill and is awaiting data from a second Phase III study.

The Cambridge, MA-based, privately held biotech expects data from a second Phase III trial in the third quarter and is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Therapy Areas